Ibex Solutions News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lonza Group AG: Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp New agreement for three further production lines at Lonza's site in Visp, Switzerland Additional production lines will come online sequentially All three are expected to be operational in the earlier part of 2022 Quote from Pierre-Alain Ruffieux, CEO, Lonza: "Since we began working with Moderna in May 2020, its mRNA vaccine has proved to be pivotal in controlling the COVID-19 pandemic. We have commenced and ramped up operations in our four existing production lines at an unpr...

A new agreement with Moderna will see Lonza add three more production lines at its site in Visp, Switzerland. Additional production lines will come online sequentially, said the contract development and manufacturing organization (CDMO). All three are expected to be operational in the earlier part of 2022 In May 2020, Lonza and Moderna announced a 10-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional products from the US biotech in the future. Since then, Lonza has installed three production lines at its...